Illumina, Inc. $ILMN Shares Sold by GUARDCAP ASSET MANAGEMENT Ltd

GUARDCAP ASSET MANAGEMENT Ltd reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,851,798 shares of the life sciences company’s stock after selling 185,639 shares during the period. Illumina comprises approximately 4.1% of GUARDCAP ASSET MANAGEMENT Ltd’s portfolio, making the stock its 13th largest position. GUARDCAP ASSET MANAGEMENT Ltd owned approximately 1.20% of Illumina worth $175,865,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of ILMN. Parkside Financial Bank & Trust lifted its holdings in shares of Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 115 shares during the last quarter. Quent Capital LLC purchased a new position in Illumina during the 3rd quarter worth approximately $29,000. Cullen Frost Bankers Inc. acquired a new position in Illumina during the second quarter worth approximately $41,000. NewSquare Capital LLC lifted its stake in Illumina by 604.9% in the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after buying an additional 369 shares during the last quarter. Finally, Mather Group LLC. acquired a new stake in shares of Illumina in the third quarter valued at approximately $46,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity

In other Illumina news, insider Scott M. Davies sold 323 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This trade represents a 1.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.17% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ILMN. Stifel Nicolaus boosted their price target on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Zacks Research downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Barclays upped their price target on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. JPMorgan Chase & Co. decreased their price target on Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a report on Friday. Finally, UBS Group reissued a “neutral” rating and issued a $135.00 price objective on shares of Illumina in a research note on Friday. Six investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $129.17.

Illumina Price Performance

ILMN opened at $117.25 on Tuesday. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $155.53. The company’s 50 day simple moving average is $138.20 and its 200 day simple moving average is $116.41. The stock has a market capitalization of $17.92 billion, a PE ratio of 21.51, a P/E/G ratio of 1.98 and a beta of 1.45. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the prior year, the business earned $0.95 earnings per share. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.